-
Mashup Score: 2
LCRF announces its 2023 requests for proposals in lung cancer research are now being accepted. Read more for deadlines and requirements.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety results of …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Final results from LIBRETTO 001 (phase I/II selpercatinib for #RET fusion NSCLC) @JCO_ASCO. In first-line, RR 83%, DOR 20.3m, PFS 22m, OS NR after 43m. In later lines, RR 62%, DOR 31.6m, PFS 26.2m, OS 47.6m. CNS RR 85%, CNS PFS 11m. Be sure to test! https://t.co/3myU9HxeU2
-
-
Mashup Score: 7Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations - 11 day(s) ago
Improved understanding of lung cancer biology and incorporation of next generation sequencing (NGS) has identified subsets of lung cancers, particularly those with mutations in non-small cell lung cancer (NSCLC) which are key in oncogenesis [1,2] The earliest actionable driver mutations identified in NSCLC were within the epidermal growth factor receptor (EGFR; exon 19 deletions and exon 21 L858R) and anaplastic lymphoma kinase (ALK; fusions) genes, and standard of care treatment for all stages of NSCLC with such mutations now includes targeted tyrosine kinase inhibitors (TKIs) such as osimertinib and alectinib [3],respectively.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
TP53 co-mutations portend poor prognosis in NSCLC with driver alterations @LungCaJournal. Presence of TP53 mt associated with shorter OS, shorter PFS on 1L therapy (5m vs 10m), lower RR to 1L targeted therapy (62% vs 70%), and more PD as best response. https://t.co/OYD9up8Z3m
-
-
Mashup Score: 5Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations - 15 day(s) ago
The Kirsten rat sarcoma oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small-cell lung cancer (NSCLC), occurring in approximately 30 % of cases [1]. KRAS mutations are heterogeneous, displaying variability in their oncogenic potential, therapeutic implications, and prognostic significance [2]. Among these, the KRAS G12C and KRAS G12D variants are of particular interest, with an estimated prevalence of 15 % and 4 %, respectively, in NSCLC [2,3]. While several targeted therapies have been developed and approved for KRAS G12C, including sotorasib and adagrasib, KRAS G12D −directed agents remain in the early stages of clinical development [4,5].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Real world outcomes of #KRAS G12C and G12D NSCLC @LungCaJournal (n=298). KRAS G12D with 15% never smokers & 36% PDL1 neg. For G12D, similar survival for IO, chemo-IO, and chemo. For G12C, better OS with IO (HR 0.61) or chemo-IO (HR 0.59) vs chemo alone. https://t.co/BQ9sYfP6ty
-
-
Mashup Score: 35Facility-Level Disparities in Radiation Use for Limited-Stage Small Cell Lung Cancer | JCO Oncology Practice - 16 day(s) ago
PURPOSETreatment of limited-stage small cell lung cancer (LS-SCLC) with twice-a-day radiation therapy (RT) has remained the standard of care for many decades. Growing evidence suggests that outcomes with dose escalated twice-a-day RT may further improve …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Report on radiation for limited stage #SCLC @JCOOP_ASCO. While the data for bid radiation are strong, it is under utilized. In this study - among 1,222 facilities, only 52.7% had even one patient receive BID radiation. More common in academic sites. https://t.co/ge50SLeCVc
-
-
Mashup Score: 65
Non-bacterial thrombotic endocarditis (NBTE) is a rare but serious complication of malignant neoplasms, most commonly non-small cell lung cancer (NSCLC). NBTE can frequently present with neurological symptoms caused by arterial embolisms. These embolisms can significantly impact the short-term prognosis of patients, making early and effective diagnosis and treatment crucial.The molecular characterization of NSCLC has led to the development of targeted therapies, such as tyrosine kinase inhibitors (TKIs), which have significantly improved the prognosis of patients with driver mutations.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet-
An interesting presentation of #ROS1 NSCLC described @ClinicalLung. Two cases of patients with nonbacterial thrombotic endocarditis - these can lead to dangerous arterial thrombotic complications. Here, treatment with crizotinib was effective. https://t.co/V89Ftvrz5r
-
-
Mashup Score: 146The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population - 19 day(s) ago
While osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, as the first-line therapy for metastatic non-small cell lung cancer (NSCLC) has shown significant survival benefits, concerns have arisen regarding its potential cardiotoxicity, particularly in real-world clinical settings. We aimed to investigate the incidence, risk factors, and reversibility of osimertinib-related cardiotoxicity.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Cardiotoxicity of osimertinib in real world population with #EGFR NSCLC @JTOonline. In 1126 pts, incidence of osimertinib-related cardiac dysfunction was 4.7% (3.4% required some intervention). Recovery rate was 82.4% (similar if discontinued or not). https://t.co/t41aDXmvmN
-
-
Mashup Score: 139Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study - 19 day(s) ago
Small-cell lung cancer (SCLC) has limited second-line treatment options after chemotherapy. We assessed the efficacy and safety of lurbinectedin combined with pembrolizumab in relapsed SCLC patients who had not received prior immunotherapy, aiming to prevent early progression and achieve sustained responses.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Results from phase I/II LUPER study of lurbinectedin + pembrolizumab in #SCLC @JTOonline. RR 46.4% including 3 CR with DOR 7.8m, PFS 4.6m, OS 10.5m. In platinum sensitive, PFS 8m, OS 15.7m. Combination data relevant in light of forthcoming IMforte data. https://t.co/1WPfyBvqd0
-
-
Mashup Score: 70Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors - 20 day(s) ago
Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in KRASG12C cancers. However, resistance invariably develops, resulting in short-lived responses. We aimed to define the genomic landscape of acquired resistance to KRASG12Ci and to elucidate whether novel classes of KRAS inhibitors can overcome these resistance mechanisms.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
What do we know about acquired resistance to #KRAS G12C inhibitors? Report @Annals_Oncology notes RAS/MAPK alterations are responsible in CRC > NSCLC including KRAS mts and amp, RAF/MAPK mt and fusions, KRAS switch-II pocket mt, and NRAS/HRAS mts. https://t.co/RuLCUNJJ6T
-
-
Mashup Score: 41Risk factors for locoregional relapse after segmentectomy: Supplementary analysis of the JCOG0802/WJOG4607L trial - 20 day(s) ago
The JCOG0802/WJOG4607L trial revealed superior overall survival in segmentectomy to lobectomy for small-peripheral non-small-cell lung cancer. However, locoregional relapse (LR) is a major issue for segmentectomy. An ad hoc supplementary analysis aimed to determine the risk factors for LR and the degree of advantages of segmentectomy based on primary tumor sites.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Analysis of locoregional relapse after segmentectomy in JCOG0802 @JTOonline. Multivariable analysis associates pure-solid on thin-section CT (OR 3.23), margin < tumor size (OR 2.68), & male sex (OR 2.09) with LR. Trend in left lingular segment site. https://t.co/ENfJmTT0Pm
-
RT @lcrf_org: RFP Open: https://t.co/UejfzLEtbw Submissions are being accepted for a $500K, two-year award titled: LCRF | Bayer Research Aw…